大于五厘米胸腺瘤机器人切除术后的复发率和存活率

IF 1.9 3区 医学 Q3 ONCOLOGY Journal of Surgical Oncology Pub Date : 2025-03-28 DOI:10.1002/jso.28098
John M. Campbell, Peter T. White, Adam J. Bograd, Alexander S. Farivar, Candice L. Wilshire, Eric Vallières, Brian E. Louie
{"title":"大于五厘米胸腺瘤机器人切除术后的复发率和存活率","authors":"John M. Campbell,&nbsp;Peter T. White,&nbsp;Adam J. Bograd,&nbsp;Alexander S. Farivar,&nbsp;Candice L. Wilshire,&nbsp;Eric Vallières,&nbsp;Brian E. Louie","doi":"10.1002/jso.28098","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background and Methods</h3>\n \n <p>Minimally invasive large thymoma resection remains controversial given the paucity of long-term oncological outcomes. We described the recurrence and survival of patients with thymomas ≥ 5 cm resected robotically.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Consecutive thymoma resections between January 2006 and December 2022 were reviewed. Thymic carcinoma/neuroendocrine tumors, induction therapy treatment, and Stage IV disease were excluded. For thymomas ≥ 5 cm, open versus robotic resections were compared. With robotic resections, thymomas ≥/&lt; 5 cm were compared. The outcomes were freedom from recurrence (FFR) and overall survival (OS).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>There were 40 thymomas ≥ 5 cm (15 open and 25 robotic) and 52 robotic thymoma &lt; 5 cm resections. Median follow-up was 5 years with 4 (4%) patients having recurrences and 5 (5%) demised.</p>\n \n <p>In thymomas ≥ 5 cm, patients were similar, except for higher comorbidities in the open cohort. Five-year FFR (<i>p</i> = 0.42) and OS (<i>p</i> = 0.34) were comparable.</p>\n \n <p>Patients with robotic resection of thymomas ≥/&lt; 5 cm were similar, except those &lt; 5 cm were more frequently Masaoka−Koga Stage II. Five-year FFR (<i>p</i> = 0.62) and OS (<i>p</i> = 0.62) were similar.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Resectable large thymomas, ≥ 5 cm, can be approached robotically with similar recurrence and survival when compared to open or smaller robotic resections. In otherwise appropriate thymomas, considerations such as location and proximity to surrounding structures, over size alone, should guide the approach.</p>\n </section>\n </div>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":"131 8","pages":"1521-1528"},"PeriodicalIF":1.9000,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Recurrence and Survival Following Robotic Resection of Thymomas Greater Than Five Centimeters\",\"authors\":\"John M. Campbell,&nbsp;Peter T. White,&nbsp;Adam J. Bograd,&nbsp;Alexander S. Farivar,&nbsp;Candice L. Wilshire,&nbsp;Eric Vallières,&nbsp;Brian E. Louie\",\"doi\":\"10.1002/jso.28098\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background and Methods</h3>\\n \\n <p>Minimally invasive large thymoma resection remains controversial given the paucity of long-term oncological outcomes. We described the recurrence and survival of patients with thymomas ≥ 5 cm resected robotically.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Consecutive thymoma resections between January 2006 and December 2022 were reviewed. Thymic carcinoma/neuroendocrine tumors, induction therapy treatment, and Stage IV disease were excluded. For thymomas ≥ 5 cm, open versus robotic resections were compared. With robotic resections, thymomas ≥/&lt; 5 cm were compared. The outcomes were freedom from recurrence (FFR) and overall survival (OS).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>There were 40 thymomas ≥ 5 cm (15 open and 25 robotic) and 52 robotic thymoma &lt; 5 cm resections. Median follow-up was 5 years with 4 (4%) patients having recurrences and 5 (5%) demised.</p>\\n \\n <p>In thymomas ≥ 5 cm, patients were similar, except for higher comorbidities in the open cohort. Five-year FFR (<i>p</i> = 0.42) and OS (<i>p</i> = 0.34) were comparable.</p>\\n \\n <p>Patients with robotic resection of thymomas ≥/&lt; 5 cm were similar, except those &lt; 5 cm were more frequently Masaoka−Koga Stage II. Five-year FFR (<i>p</i> = 0.62) and OS (<i>p</i> = 0.62) were similar.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>Resectable large thymomas, ≥ 5 cm, can be approached robotically with similar recurrence and survival when compared to open or smaller robotic resections. In otherwise appropriate thymomas, considerations such as location and proximity to surrounding structures, over size alone, should guide the approach.</p>\\n </section>\\n </div>\",\"PeriodicalId\":17111,\"journal\":{\"name\":\"Journal of Surgical Oncology\",\"volume\":\"131 8\",\"pages\":\"1521-1528\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-03-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Surgical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jso.28098\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Surgical Oncology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jso.28098","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景和方法:由于缺乏长期肿瘤预后,微创大胸腺瘤切除术仍然存在争议。我们描述了机器人切除≥5 cm胸腺瘤患者的复发和生存。方法:回顾2006年1月至2022年12月连续切除的胸腺瘤。排除胸腺癌/神经内分泌肿瘤、诱导治疗和IV期疾病。对于≥5 cm的胸腺瘤,比较开放和机器人切除。结果:≥5cm胸腺瘤有40例(开放胸腺瘤15例,机器人胸腺瘤25例),机器人胸腺瘤52例。结论:≥5cm可切除的大胸腺瘤与开放胸腺瘤或较小的机器人胸腺瘤相比,机器人胸腺瘤的复发率和生存率相似。在其他适当的胸腺瘤中,考虑诸如位置和邻近的周围结构,仅考虑过大的尺寸,应该指导入路。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Recurrence and Survival Following Robotic Resection of Thymomas Greater Than Five Centimeters

Background and Methods

Minimally invasive large thymoma resection remains controversial given the paucity of long-term oncological outcomes. We described the recurrence and survival of patients with thymomas ≥ 5 cm resected robotically.

Methods

Consecutive thymoma resections between January 2006 and December 2022 were reviewed. Thymic carcinoma/neuroendocrine tumors, induction therapy treatment, and Stage IV disease were excluded. For thymomas ≥ 5 cm, open versus robotic resections were compared. With robotic resections, thymomas ≥/< 5 cm were compared. The outcomes were freedom from recurrence (FFR) and overall survival (OS).

Results

There were 40 thymomas ≥ 5 cm (15 open and 25 robotic) and 52 robotic thymoma < 5 cm resections. Median follow-up was 5 years with 4 (4%) patients having recurrences and 5 (5%) demised.

In thymomas ≥ 5 cm, patients were similar, except for higher comorbidities in the open cohort. Five-year FFR (p = 0.42) and OS (p = 0.34) were comparable.

Patients with robotic resection of thymomas ≥/< 5 cm were similar, except those < 5 cm were more frequently Masaoka−Koga Stage II. Five-year FFR (p = 0.62) and OS (p = 0.62) were similar.

Conclusions

Resectable large thymomas, ≥ 5 cm, can be approached robotically with similar recurrence and survival when compared to open or smaller robotic resections. In otherwise appropriate thymomas, considerations such as location and proximity to surrounding structures, over size alone, should guide the approach.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.70
自引率
4.00%
发文量
367
审稿时长
2 months
期刊介绍: The Journal of Surgical Oncology offers peer-reviewed, original papers in the field of surgical oncology and broadly related surgical sciences, including reports on experimental and laboratory studies. As an international journal, the editors encourage participation from leading surgeons around the world. The JSO is the representative journal for the World Federation of Surgical Oncology Societies. Publishing 16 issues in 2 volumes each year, the journal accepts Research Articles, in-depth Reviews of timely interest, Letters to the Editor, and invited Editorials. Guest Editors from the JSO Editorial Board oversee multiple special Seminars issues each year. These Seminars include multifaceted Reviews on a particular topic or current issue in surgical oncology, which are invited from experts in the field.
期刊最新文献
The Treatment Efficacy for Patients Undergoing Combined Transanal-Transabdominal Endoscopic Resection of Rectal Anastomosis Stenosis. "It Depends on the Situation": Variability in How Surgical Oncologists Elicit and Integrate Patient Values. A Tale of Two Pathways: Same-Surgeon Versus Different-Surgeon Resection After Second Surgical Opinion. How I Do It: The Life and Work of a Rubber Band in Robotic Liver Parenchymal Transection. New Paradigms of Cancer Require New Language: A Qualitative Study Exploring Language for Non-Curative Non-Palliative Cancer Surgery.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1